Compare AHCO & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | TYRA |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | AHCO | TYRA |
|---|---|---|
| Price | $10.19 | $22.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $13.60 | ★ $31.20 |
| AVG Volume (30 Days) | ★ 1.0M | 579.0K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $3,255,213,000.00 | N/A |
| Revenue This Year | $1.07 | N/A |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | $18.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.11 | $6.42 |
| 52 Week High | $11.63 | $24.05 |
| Indicator | AHCO | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 64.17 |
| Support Level | $10.13 | $21.66 |
| Resistance Level | $10.56 | $24.05 |
| Average True Range (ATR) | 0.38 | 1.30 |
| MACD | 0.09 | -0.12 |
| Stochastic Oscillator | 71.54 | 50.94 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.